Corporate Profile
Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-gen PDE5 inhibitor designed to directly enhance nitric oxide signaling in central arteries that were previously inaccessible to first-generation PDE5 inhibitors. This addresses a core driver of hypertension. With over 30 million Americans suffering from uncontrolled or treatment-resistant hypertension – and even modest reductions in blood pressure translating into significant decreases in cardiovascular events – RTN-001 addresses a large, high-value unmet need.